AbCellera Biologics (NasdaqGS:ABCL) has drawn fresh attention after announcing a preclinical collaboration and license agreement with Jazz Pharmaceuticals focused on next generation T cell engaging multispecific antibodies for difficult gastrointestinal cancers and solid tumors.

At a share price of $5.74, AbCellera Biologics has seen momentum build recently, with a 90 day share price return of 73.41% and a 1 year total shareholder return of 72.37%, despite a weaker 3 year and 5 year total shareholder record.

If this kind of interest in antibody and oncology platforms has your attention, it may be worth seeing what else is moving in the space via the 38 healthcare AI stocks.

With AbCellera Biologics now backed by fresh Jazz Pharmaceuticals funding and the share price sharply higher over the past year, the key question is simple: is this still underappreciated, or is the market already pricing in future growth?

Most Popular Narrative: 45% Undervalued

With AbCellera Biologics last closing at $5.74 against a most followed fair value estimate of $10.43, the current price sits well below that narrative marker while analysts bake in a high bar for future execution and profitability.

The initiation of Phase I clinical trials for ABCL635 and ABCL575, with promising differentiation factors such as a unique dosing regimen and improved safety profile for ABCL635, is expected to position the company to capture a significant market opportunity in an underserved area, potentially boosting future revenue.

It raises questions about what kind of revenue reset and margin shift supporters of this fair value are assuming, and how a very large future earnings multiple fits into the story.

Result: Fair Value of $10.43 (UNDERVALUED)

However, the AbCellera Biologics story relies on successful clinical outcomes for ABCL635 and ABCL575, and ongoing widening losses could challenge confidence in those optimistic margin assumptions.

Another View: What AbCellera Biologics Looks Like On Sales Multiples

While the most followed fair value narrative points to AbCellera Biologics trading 45% below a $10.43 estimate, the current P/S ratio of 22.1x tells a very different story. It is far above the US Life Sciences industry at 3.8x, peers at 8.6x, and a fair ratio of just 0.3x, which suggests meaningful valuation risk if sentiment cools.

For investors, that gap raises a simple question: is this a justified premium for future pipeline potential, or a setup where any setback could hit the stock hard?

Next Steps

If the split in sentiment around AbCellera Biologics has you on the fence, now is a good time to review the facts for yourself and stress test the downside by understanding the 3 important warning signs.

Looking for more investment ideas beyond AbCellera Biologics?

If AbCellera Biologics has sharpened your focus, do not stop here. The next strong opportunity you research on the Simply Wall St screener could be one you are glad you did not ignore.

• Target more predictable cash generators by checking stocks in the solid balance sheet and fundamentals stocks screener (48 results) that can complement higher risk biotech exposure.
• Hunt for potential mispriced opportunities using the screener containing 19 high quality undiscovered gems that many investors may not be watching yet.
• Reduce portfolio stress by reviewing companies in the 66 resilient stocks with low risk scores that may help steady returns when sentiment swings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.